Markets

MELBOURNE, Australia, June 1, 2021 /PRNewswire/ — Australia’s Viraleze anti-COVID nasal spray is active against the highly infectious UK variant of SARS-CoV-2, the virus that causes COVID-19, reducing infectivity of the virus by >98%, it was announced today in a major development for the product.Melbourne-based biopharmaceutical company Starpharma found there was no loss of potency compared to an earlier US strain of the virus, which is irreversibly inactivated by Viraleze within one minute of exposure. The results hold out significant promise for the product given concerns with the public health impacts of new variants of SARS-CoV-2. Starpharma is also testing the Japan/Brazil and South African variants of COVID, with the results expected in the coming weeks. Testing of the Indian variant will also be undertaken when virus availability allows.The antiviral testing was conducted by the renowned Scripps Research Institute in the US, with the UK variant of SARS-CoV-2, which has been classified as a variant of concern. The UK variant was recently reported to be responsible for over 98% of the positive COVID infections in England and linked to multiple outbreaks worldwide.Internationally recognised virology researcher, Professor Philippe Gallay, at the renowned Scripps Research Institute in the US, commented: “We are impressed

June 1, 2021Breda, the Netherlands – argenx (Euronext & Nasdaq: ARGX), a global immunology company committed to improving the lives of people suffering from severe autoimmune diseases and cancer, today announced the appointment of Mr. Karl Gubitz as Chief Financial Officer. Mr. Gubitz brings to argenx nearly 20 years of global pharmaceutical leadership experience, specifically in financial planning and analysis, business partnerships and product commercialization. He will succeed Eric Castaldi, who will remain with the company through June 30, 2021.“We are delighted to welcome Karl to our executive leadership team as he has an impressive track record of successfully establishing commercial organizations and providing strategic financial direction for global biopharmaceutical companies,” said Tim Van Hauwermeiren, CEO of argenx. “Karl’s insight and financial expertise will make him an indispensable member of the team as we advance our vision of developing an integrated, innovative, global immunology organization that aims to impact the lives of patients.”“On behalf of the argenx management team and Board of Directors, we thank Eric for his significant contributions as we have grown from a private company to a near-commercial organization. It has been a pleasure working with him and we are grateful for the integral role he played

At 8:00 pm EDT on Sunday, June 6, 2021, world champion boxer Floyd Mayweather will square off against Logan Paul in the 65,326-seat Hard Rock Stadium in Miami. Under a sponsorship agreement with the Company, several members of Mr. Mayweather’s entourage will wear baseball hats with the TAAT™ logo during their entry into the arena and approach to the boxing ring. Previous boxing events featuring Mr. Mayweather set all-time records for pay-per-view demand, with his most recent professional fight against Conor McGregor yielding more than 4.3 million “buys” in August 2017.LAS VEGAS and VANCOUVER, British Columbia, June 01, 2021 (GLOBE NEWSWIRE) — TAAT™ GLOBAL ALTERNATIVES INC. (CSE: TAAT) (OTCQX: TOBAF) (FRANKFURT: 2TP) (the “Company” or “TAAT™”) has secured a high-profile sponsorship arrangement with world champion boxer Floyd Mayweather and his ringside entourage for Mr. Mayweather’s highly anticipated boxing match against Logan Paul on Sunday, June 6, 2021 at the Hard Rock Stadium in Miami, Florida. Under the sponsorship agreement, between six and eight of Mr. Mayweather’s entourage personnel will wear a TAAT™ baseball hat with the logo made clearly visible during their entry to the arena and approach towards the boxing ring, which will be visible to the live audience

BEIJING, June 1, 2021 /PRNewswire/ — “Boundless is the ocean where we sail with the wind” is a line from a Chinese poem written 1,000 years ago. The ancient saying, which means there are no geographical limits to where we travel to meet friends, has enduring resonance in modern China.”I wish to make it clear to all that China’s door of opening-up will not be closed and will only open even wider,” said Chinese President Xi Jinping at the Boao Forum for Asia in 2018.From reform and opening-up… The remarkable changes that resulted from China’s 1978 reform and opening-up policy testify to the great value of the conviction that openness is the way to growth and wealth.Guided by the policy, the country has been transformed from a largely agricultural nation to the second largest economy in the world.China’s total imports and exports of goods expanded 1.9 percent year on year to 32.16 trillion yuan (about $4,647 billion) in 2020, hitting a record high despite a worldwide slump in shipments and making it the world’s only major economy to register positive growth in foreign trade in goods.In 1978, the volume totaled only about $20.6 billion.China has worked hard to attract

NEW YORK, June 1, 2021 /PRNewswire/ — Despite tireless efforts by health care workers and major breakthroughs with Covid-19 vaccines, more than 10,000 people a day around the world are still dying from Covid-19. The continued spread of the virus in unvaccinated populations threatens to keep the global economy choked for the foreseeable future and pose threats to current progress in containing the pandemic. To stop the spread of this pandemic, all countries need equal access to Covid-19 vaccination. A new report by The Rockefeller Foundation and key collaborators, One for All: An Updated Action Plan for Global Covid-19 Vaccination, is the first to present financing models that could drive the global vaccination effort forward. More than 80 percent of shots have gone into arms in high- and upper-middle income countries, leaving the pandemic to spread unchecked in lower-income countries and the world at risk of viral variants and reignited pandemic spread.  But that inequity and the lack of a well-resourced global vaccination campaign extends beyond a health crisis. Our interconnected global economy stands to lose as much as US$9.2 trillion this year if governments fail to ensure developing economies have access to Covid-19 vaccines, and  at least half of that loss

HONG KONG, June 1, 2021 /PRNewswire/ — Acclime, the premier corporate services provider in Asia, is pleased to announce today that its Australian subsidiary, CoSec Corporate Services, has completed its integration into the Acclime group of companies. Following the acquisition by Acclime earlier this year, CoSec Corporate Services has now fully rebranded to Acclime Australia. In addition to its presence in nine key Asian jurisdictions and a European sales office in the Netherlands, Acclime’s footprint now extends into Australia, with additional sales offices in San Francisco and Denver in the United States of America, and the United Kingdom. Founded by Blair Lucas and Paul Dixon in 2011, CoSec Corporate Services offers clients entering and operating in Australia and the USA a full suite of incorporation and ongoing corporate compliance, accounting, and tax services. The firm has extensive experience in assisting companies from across a wide variety of industry sectors, including life sciences, fintech, agtech and energy, to enter the lucrative Australian market. Since founding, CoSec has supported more than 500 companies from 38 countries to expand their operations into Australia.Blair Lucas and Paul Dixon will continue to lead the Australia team within the Acclime family as CEO and CFO respectively and

(RTTNews) – Indian shares look set to open a tad higher on Tuesday as investors cheer better-than-expected macroeconomic data. India’s economy shrank 7.3 percent in the fiscal year ended March 31, preliminary estimates from the statistics ministry showed. The government had earlier forecast 8.0 percent decline in gross domestic product for the year during which economic activity was severely hurt by the coronavirus pandemic. In the January to March quarter, the economy grew 1.6 percent year-on-year, which was faster than the 1.0 percent expansion that economists had forecast. The December quarter growth was revised to 0.5 percent from 0.4 percent. Meanwhile, the output of eight core sectors jumped by as much as 56.1 percent in April mainly due to a low base effect and uptick in production of natural gas, refinery products, steel, cement and electricity. Separate government data showed that the country’s fiscal deficit for the financial year 2020-21 was 9.3 percent of GDP, which was less than the 9.5 percent estimated earlier. Benchmark indexes Sensex and the Nifty jumped about 1 percent on Monday, while the rupee dropped 17 paise to close at 72.62 against the dollar, snapping a three-day winning streak. Asian

Tesla Model Y. Tesla

SINGAPORE, June 1, 2021 /PRNewswire/ — AVATAMED (www.avatamed.com), a precision medicine service company based in Singapore, announced the setting up of a joint lab with Singapore’s Institute of Molecular and Cell Biology (IMCB) at the Agency for Science, Technology and Research (A*STAR), to offer precision oncology services. Through this initiative, AVATAMED and IMCB aim to improve treatment outcome for cancer patients.Globally, there are about 10 million cancer deaths every year and this number will increase over the years. Even with advances in new cancer therapeutics such as immunotherapy, and diagnostics such as genetic testing, there are still huge unmet needs of various groups of patients.Precision oncology provides targeted treatment for individual cancer patients based on their clinical, tumour and genetic profiles. This approach has helped many patients whose tumours do not respond to the standard-of-care treatments, have limited treatment options or have become resistant to the anti-cancer drugs.The joint service lab is located within IMCB’s premises at Proteos building in Biopolis, the heart of Singapore’s Biotechnology hub. Together with IMCB’s technological platforms such as the high-throughput drug screening platform, and expertise in cancer and cell biology, the joint service lab will offer AVATAMED’s proprietary drug screening technology, the AVATASCAN and

SAN FRANCISCO and SUZHOU, China, June 1, 2021 /PRNewswire/ — Innovent Biologics, Inc. (Innovent) (HKEX: 01801), a world-class biopharmaceutical company that develops, manufactures and commercializes high-quality medicines for the treatment of cancer, metabolic, autoimmune and other major diseases, and AnHeart Therapeutics Co., Ltd. (“AnHeart”), a clinical stage oncology company focused on underserved patients in global markets, today jointly announce an exclusive license agreement for the co-development and commercialization of AnHeart’s lead drug candidate, taletrectinib – a next-generation tyrosine kinase inhibitor (TKI) designed to effectively target ROS1 and NTRK – in Greater China, including mainland China, Hong Kong, Macau and Taiwan.Under the terms of the agreement, Innovent will obtain exclusive rights to co-develop and commercialize taletrectinib in Greater China. AnHeart will continue to be responsible for the development of taletrectinib up to regulatory approval in mainland China and for supplying taletrectinib for both developmental and commercial purposes in Greater China. Innovent has the right to co-develop taletrectinib in Hong Kong, Macau and Taiwan up to regulatory approval. According to the agreement, AnHeart will receive an upfront payment, R&D fees, and potential milestone payments totaling USD189 million in addition to tiered royalties based on annual net sales of taletrectinib in Greater China. Taletrectinib is currently